David Fellows - Chairman

David Fellows

Chairman
David was Chief Executive Officer of NightstaRx and led the company through a successful NASDAQ listing and M&A transaction. He was previously Vice President of Johnson & Johnson’s Vision Care Franchise and Regional President at Allergan plc. David is Chairman of Oxular Limited and is a board member of the Glaucoma Foundation.
Thomas Cavanagh - Chief Executive Officer

Thomas Cavanagh

Director and CEO

Thomas is a co-founder, the Chief Executive Officer and a Board member of Oxular Limited. He is an experienced and successful entrepreneur who has helped to build four previous private equity-backed ventures. He was formerly co-founder and Chief Executive Officer of Aciex Therapeutics, where he brought its lead program to NDA and led the company through a successful M&A exit. 

Ronald Yamamoto - Chief Scientific Officer

Ronald Yamamoto

Director and CSO
Ronald is a co-founder, the Chief Scientific Officer and a Board member of Oxular Limited. He brings more than 30 years of medical device and drug product development experience. Ronald has developed novel ophthalmic microcatheters for surgical treatment of glaucoma and retinal disease, sub-retinal access devices, diagnostic microspheres and drug-releasing implants. He was previously a co-founder and Chief Scientific Officer of iScience Interventional.

Dr. Rafiq Hasan

Director
Rafiq is the CEO of EXACT-Therapeutics, a clinical stage Anglo-Norwegian biotech company. An MD by training, Rafiq has 25 years in the pharma industry globally. As SVP and Global Head of Ophthalmology at Bayer, he grew the business of Eylea® from launch to over $2.5bn in five years, including its launch in five indications in three years.
Dina Chaya - Director

Dina Chaya

Director

Dina is a partner with NeoMed. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. She was previously at 3i plc in London and Index Ventures in Geneva and has worked in the private equity and venture capital healthcare industry in Europe and the US since 2001. Dina is a Board member of Oxular Limited and TopiVert Ltd. She is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France and carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US. 

Christina Takke - Director

Christina Takke

Director

Christina is co-founder and Managing Director of V-Bio VenturesChristina has more than 15 years of investment experience in European Venture Capital. She was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina has a scientific background, holding a PhD in Developmental Biology from the University of Cologne, Germany, and an MSc in Biology from the University of Darmstadt, Germany.

Tassos Konstantinou- Director

Tassos Konstantinou

Director

Tassos is an Investment Manager at IP Group. He specialises in early stage investing in the life science sector. Before joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (ex CRT) where he led the intellectual property sourcing, licensing and spin-out creation of CRUK-funded technologies. He has experience in technology transfer both in the states and the UK and has also held an investment analyst role with SR One, GSK’s venture capital arm. Tassos did a PhD in molecular oncology at the University of Oxford and a postdoc at the University of Chicago.

Scroll to Top